UK Markets closed

Acurx Pharmaceuticals, Inc. (ACXP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.6900+0.1400 (+3.94%)
At close: 04:00PM EDT
3.8400 +0.15 (+4.07%)
After hours: 07:50PM EDT
Sign in to post a message.
  • b
    I keep buying at these lows. Hard to believe it was in the 2.30;s recently, and still low volume. 2B only months away.
  • m
    Loading up. This is too cheap and could be a 12x on 2B
  • m
    Folks. 2B is all that matters. Expect muted movement until 2B results are released. Could get a grant which would likely provide a good move but stil.. 2B. All that matters
  • g
    Buying more
  • B
    Somebody wanted out today. Why sell at a low?
  • L
    Lost it
    Margin call?
  • b
    Finally some good signs, with the stock price going from 3.11, to $4 Thursday. a lot of big buys this week had the stock moving nicely. Looking for some info comming in next week
  • D
    I just bought 1.5k should i worry?
  • M
    Incredible P2A data - patients have been 100% cured with no recurrence of CDI. P2b data should confirm and launch this thing to the moon. I got in pre-IPO and really like the odds here.
  • m
    Summit didn’t meet their phase 3 endpoint. Summit was ACXP’s primary competition. Let the buss begin!
  • m
    $20+ in 8 months or less
    $50+ in 18 months

    Total hidden gem
  • W
    Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference

    See Yahoo headline
  • a
    Stock will be over $25 on good phase 2B data.
  • D
    I'm in. Sounds like a winner.
  • D
    Is there always a Phase 2b before going on to Phase 3? I don't recall this with other bio's that I've owned. Regardless, good news this AM.
  • D
    Appears good price entry IPO
  • D
    Here we go. Antibiotics are "easy" FDA approval. New class, targeting resistant bacteria.
  • m
    -100% cure. 0% recurrence. Way better than vanco. Way better than summit.
    -30% insider ownership
    -continual insider buying
    -500M sales at only 20% market penetration
    -most compelling pick according to biopub
    -pasteur act potential
    -best medical advisor board
    -restores microbiome unlike any other option
    -amr fund potential
    - Novo nordisk fund potential
    -icing in the cake is 1B sales on their clinical stage acx-375 if approved and achieves only 4% penetration

    If they are front line drug for cdiff and have a ps ratio of 4 that implies a market cap of 6B. Which would be a 125x upside

    125x plus whatever they get from axc-375
  • D
    Insiders acquired a ton of shares at month end. Very good news.
  • w
    what price coming out at